| INTRODUCTION
Crohn's disease is an idiopathic chronic inflammatory bowel disease characterised by transmural inflammation resulting in inflammatory, stricturing, and fistulising phenotypes. Since the Food and Drug Administration's approval of infliximab in 1998, biologic therapy has replaced corticosteroid therapy as the dominant class of therapeutics used to medically manage moderate to severe Crohn's disease. The most widely studied and prescribed have been the anti-tumour necrosis factor-alpha (TNFa) agents (infliximab, adalimumab and certolizumab pegol). Unfortunately, up to a third of anti-TNFa-treated patients have a primary nonresponse [1] [2] [3] [4] and another third will have a secondary loss of response. 5, 6 In addition, anti-TNFa agents have been associated with adverse events such as serum sickness-like reactions, drug-induced lupus, and opportunistic infections. [7] [8] [9] [10] [11] [12] [13] [14] [15] Therefore, ongoing investigation for additional targeted therapies with alternative mechanisms and side effect profiles has been prioritised.
There was great enthusiasm following the Food and Drug
Administration's approval of vedolizumab (Entyvio TM , Takeda Pharmaceuticals America, Inc., Deerfield, IL, USA), a monoclonal antibody to a4b7-integrin, for the treatment of moderately to severely active ulcerative colitis and Crohn's disease due to its gut selectivity and therefore theoretically more favourable safety profile. The pivotal GEMINI studies demonstrated both the efficacy and safety of vedolizumab in achieving clinical relevant endpoints in Crohn's disease patients who were either na€ ıve to or had previously failed therapy with TNFa-antagonists. 16, 17 Several additional reports have demonstrated safety and efficacy with vedolizumab, [18] [19] [20] [21] [22] offering a promising alternative to the anti-TNFa class of biologic therapy.
Interestingly, despite the noted safety, the GEMINI studies suggest that patients with Crohn's disease, unlike ulcerative colitis, may have an increased number of infectious complications with taking vedolizumab. 16, 17, 23 Despite biologic therapy, 60%-80% of patients with Crohn's disease will require an abdominal operation in their lifetime. [24] [25] [26] As vedolizumab becomes more widely used for the medical management of Crohn's disease, an increasing number of patients are being exposed to vedolizumab in the perioperative period. We previously reported an increased number of postoperative infectious complications among surgical patients with inflammatory bowel disease who had received vedolizumab within 12 weeks of an abdominal operation, and found vedolizumab to be an independent predictor of surgical infectious complications on multivariate analysis. 27 Due to the increased risk of infectious complications among Crohn's disease patients as compared to those with ulcerative colitis in the GEMINI trials, and the increased number of anastomoses constructed in
Crohn's disease patients as compared to those with ulcerative colitis, we updated our previous database to compare the rate of postoperative infectious complications among Crohn's disease patients who had received vedolizumab within 12 weeks of a major abdominal operation to that of Crohn's disease patients who had received either TNFa inhibitors or no biologic therapy. had been exposed to three prior TNFa inhibitors, and 7 (7%) had been exposed to all three TNFa inhibitors in addition to ustekinumab prior to initiation of therapy with vedolizumab. Thirty one patients (31%) and 49 patients (49%) were receiving corticosteroid therapy and immunomodulator therapy, respectively, at the time of operation, compared to 37 (35%) and 18 (17%) in the TNFa inhibitor biologic group and 22 (21%) and 38 (36%) in the nonbiologic group, respectively (P = .08 and P < .001 respectively). Within 30 of surgery, the median leucocyte count was 8.6 g/dL, haemoglobin was 11.4 g/dL, platelet count was 345 9 10 9 /L, serum albumin was 3.7 g/dL, and Creactive protein was 29.3 mg/dL, of which the leucocyte count and platelet count were significantly different from the corresponding values in the TNFa inhibitor and nonbiologic groups (P < .0001 and (29) 33 (31) 23 (23) B3p 27 8 (8) 7 (7) 12 (12) TNF, tumour necrosis factor-alpha; BMI, body mass index; CRP, C-reactive protein; IMM, immunomodulator.
| MATERIALS AND METHODS
T A B L E 1
T A B L E 2 Operative characteristics of Crohn's disease patients
No biologic Therapy (n = 105) | 577 patients (17%) had a superficial surgical site infection treated with opening the wound and/or antibiotics, 6 (6%) had a deep space surgical site infection treated with percutaneous drainage and antibiotics, and one (2%) experienced an anastomotic leak. Seven patients (13%) had separation of the mucocutaneous border requiring intervention.
Twenty-one (21%) experienced a small bowel obstruction or ileus.
Twenty-two patients (22%) had an unplanned hospital readmission within 30 days, and 12 (12%) had a return to the operating room.
Returns to the operating room were performed for stoma repair/revision (n = 6), washout for unidentified perforation (n = 3), anastomotic leak (n = 1), stoma abscess washout (n = 1), and small bowel obstruction from intussuscepted bowel. There was no 30-day mortality. The vedolizumab group had a significantly increased rate of all surgical site infections (P < .001), superficial surgical site infections (P = .0037), mucocutaneous separation (P < .0001), small bowel obstruction/ileus (P = .008) and readmission (P = .003) but not deep space surgical site infection (P = .26), anastomotic leak (P = .14), small bowel obstruction/ileus (P = .1449), 30-day unplanned hospital readmission (P = .07) or 30-day return to the operating room (P = .09) ( Table 3 ).
Within the vedolizumab study group, there were no significant dif- (Table 4) On univariate analysis of the entire cohort, use of vedolizumab (P < .001), increased body mass index (P = .01), less abdominal surgery (P = .04) and fewer anastomoses (P = .02) were found to be significantly associated with surgical site infections among Crohn's disease patients. (Table 5 ) On multivariable analysis, perioperative use of vedolizumab (OR, 3.4; 95% CI, 1.5-8.2; P = .002) was predictive of surgical site infection. (Table 6 ) Interestingly, on multivariable analysis, neither perioperative use of TNFa inhibitors nor obesity was associated with the development of surgical site infections. (Table 6) When the rates of surgical infectious complications were com- Crohn's disease patients, especially infectious complications. 35 Interestingly, while controversial, the same findings have not been found in ulcerative colitis patients, with the overwhelming majority of studies reporting no added risk with preoperative exposure to infliximab, [36] [37] [38] except perhaps in pouch patients. 39 Our Vedolizumab is an effective alternative to anti-TNFa therapy for the treatment of moderate to severe Crohn's disease, with a theoretically improved safety profile due to its gut-specific mechanism of action. As its use increases, it is expected that more patients referred to surgery will be receiving vedolizumab therapy. We found a 26%
30-day surgical site infection rate and 32% postoperative infectious complication rate in patients receiving vedolizumab in the perioperative period, a rate significantly higher than that seen in patients treated with TNFa inhibitors. While vedolizumab-treated Crohn's disease patients may be a sicker cohort of patients, it is important to consider these findings with regard to preoperative counselling, operative timing, and primary closure of wounds. 
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